SOVREMENNAYA PEDIATRIYA.2018.7(95):65-68; doi 10.15574/SP.2018.95.65

Makieieva N., Odinets Yu., Poddubnaya I.
Kharkiv National Medical University, Ukraine
Communal non–profit enterprise «Municipal Clinical Children's Hospital No.16» of the Kharkiv City Council, Ukraine

Lymphomas occupy the third place in the structure of malignant tumors in children and are divided into two main types: Hodgkin's disease and non-Hodgkin's lymphoma (NHL). All types of NHL in children are tumors of a high degree of malignancy that indicates to very rapid and diffuse growth. Large cell lymphoma is up to 30% of all NHL in children. NHL in children is a systemic disease, even with one tumor lesion at the time of diagnosis. Therefore, as a rule combined chemotherapy is used. Autologous or allogenous bone marrow and peripheral stem cell transplantation is used in some patients with NHL with an incomplete response to treatment or recurrence of the disease.

Objective: to identify the role of biochemical, molecular genetic and immunohistochemical markers in the development of resistance in the treatment of lymphomas in children.

Materials and methods: A thorough biochemical, molecular genetic and immunohistochemical examination of the child and the analysis of the unfavorable out-come were carried out.

Results: An unfavorable role of some markers in the development of resistance in the treatment of lymphomas in children was confirmed based on biochemical, molecular genetic and immunohistochemical examinations.

Conclusions: In children suffering from non-Hodgkin's lymphomas, in the early stages, it is necessary to conduct modern biochemical, immunohistochemical and molecular genetic research methods, which will allow a differentiated approach to the treatment of this disease.

Key words: resistance, lymphomas, children.

REFERENCES

1. Basem Magdy William, Navneeth Rao Bongu, Martin Bast et al. (2013). The utility of lactate dehydrogenase in the follow up of patients with diffuse large B-cell lymphoma. Rev Bras Hematol Hemoter. 35(3): 189–191. https://doi.org/10.5581/1516-8484.20130054

2. Chapuy B, Stewart C, Dunford AJ. (2018). Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 24(5): 679–690. https://doi.org/10.1038/s41591-018-0016-8; PMid:29713087

3. Levashov AS, Valiyev TT, Kovrigina AM, Popa AV, Mentkevich GL. (2015). Modern oncology. 3: 30-41.

4. Li S, Young KH, Medeiros LJ. (2018). Diffuse large B-cell lymphoma. Pathology. 50(1): 74-87. https://doi.org/10.1016/j.pathol.2017.09.006; PMid:29167021

5. Qunling Zhang, Juan J Gu, Cory Mavis et al. (2016). The Adhesion Molecule ICAM-1 in Diffuse Large B-Cell Lymphoma Post-Rituximab Era: Relationship with Prognostic Importance and Rituximab Resistance. Blood. 128: 4212.

6. Swerdlow S, Campo E, Harris NL et al. (2008). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (Medicine). Lyon, France: IARC: 439.

Article received: May 07, 2018. Accepted for publication: Nov 04, 2018.